6XH0 image
Entry Detail
PDB ID:
6XH0
Title:
Co-crystal structure of HIV-1 TAR RNA in complex with lab-evolved RRM TBP6.9
Biological Source:
PDB Version:
Deposition Date:
2020-06-18
Release Date:
2020-10-14
Method Details:
Experimental Method:
Resolution:
3.10 Å
R-Value Free:
0.28
R-Value Work:
0.22
R-Value Observed:
0.23
Space Group:
P 43 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:TAR binding protein 6.9
Chain IDs:A
Chain Length:87
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polyribonucleotide
Description:TRANS-ACTIVATION RESPONSE ELEMENT
Chain IDs:B (auth: D)
Chain Length:27
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Ligand Molecules
Primary Citation
Co-crystal structures of HIV TAR RNA bound to lab-evolved proteins show key roles for arginine relevant to the design of cyclic peptide TAR inhibitors.
J.Biol.Chem. 295 16470 16486 (2020)
PMID: 33051202 DOI: 10.1074/jbc.RA120.015444

Abstact

RNA-protein interfaces control key replication events during the HIV-1 life cycle. The viral trans-activator of transcription (Tat) protein uses an archetypal arginine-rich motif (ARM) to recruit the host positive transcription elongation factor b (pTEFb) complex onto the viral trans-activation response (TAR) RNA, leading to activation of HIV transcription. Efforts to block this interaction have stimulated production of biologics designed to disrupt this essential RNA-protein interface. Here, we present four co-crystal structures of lab-evolved TAR-binding proteins (TBPs) in complex with HIV-1 TAR. Our results reveal that high-affinity binding requires a distinct sequence and spacing of arginines within a specific β2-β3 hairpin loop that arose during selection. Although loops with as many as five arginines were analyzed, only three arginines could bind simultaneously with major-groove guanines. Amino acids that promote backbone interactions within the β2-β3 loop were also observed to be important for high-affinity interactions. Based on structural and affinity analyses, we designed two cyclic peptide mimics of the TAR-binding β2-β3 loop sequences present in two high-affinity TBPs (KD values of 4.2 ± 0.3 and 3.0 ± 0.3 nm). Our efforts yielded low-molecular weight compounds that bind TAR with low micromolar affinity (KD values ranging from 3.6 to 22 μm). Significantly, one cyclic compound within this series blocked binding of the Tat-ARM peptide to TAR in solution assays, whereas its linear counterpart did not. Overall, this work provides insight into protein-mediated TAR recognition and lays the ground for the development of cyclic peptide inhibitors of a vital HIV-1 RNA-protein interaction.

Legend

Protein

Chemical

Disease

Primary Citation of related structures